company background image
ATRC

AtriCure NasdaqGM:ATRC Stock Report

Last Price

US$52.62

Market Cap

US$2.4b

7D

2.3%

1Y

-27.7%

Updated

15 Aug, 2022

Data

Company Financials +
ATRC fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance2/6
Financial Health4/6
Dividends0/6

ATRC Stock Overview

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.

AtriCure, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AtriCure
Historical stock prices
Current Share PriceUS$52.62
52 Week HighUS$89.18
52 Week LowUS$32.84
Beta1.2
1 Month Change20.27%
3 Month Change22.15%
1 Year Change-27.74%
3 Year Change91.49%
5 Year Change137.67%
Change since IPO273.72%

Recent News & Updates

Aug 02
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Does the August share price for AtriCure, Inc. ( NASDAQ:ATRC ) reflect what it's really worth? Today, we will estimate...

Shareholder Returns

ATRCUS Medical EquipmentUS Market
7D2.3%2.3%3.6%
1Y-27.7%-19.6%-9.6%

Return vs Industry: ATRC underperformed the US Medical Equipment industry which returned -19.1% over the past year.

Return vs Market: ATRC underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is ATRC's price volatile compared to industry and market?
ATRC volatility
ATRC Average Weekly Movement6.7%
Medical Equipment Industry Average Movement9.4%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ATRC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ATRC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000875Mike Carrelhttps://www.atricure.com

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes.

AtriCure, Inc. Fundamentals Summary

How do AtriCure's earnings and revenue compare to its market cap?
ATRC fundamental statistics
Market CapUS$2.44b
Earnings (TTM)US$53.34m
Revenue (TTM)US$302.78m

45.8x

P/E Ratio

8.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATRC income statement (TTM)
RevenueUS$302.78m
Cost of RevenueUS$76.43m
Gross ProfitUS$226.36m
Other ExpensesUS$173.01m
EarningsUS$53.34m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.15
Gross Margin74.76%
Net Profit Margin17.62%
Debt/Equity Ratio13.1%

How did ATRC perform over the long term?

See historical performance and comparison